Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) Enterprise Value (2019 - 2026)

Pliant Therapeutics has reported Enterprise Value over the past 8 years, most recently at -$170.9 million for Q1 2026.

  • Quarterly Enterprise Value rose 44.09% to -$170.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$170.9 million through Mar 2026, up 44.09% year-over-year, with the annual reading at -$190.9 million for FY2025, 46.32% up from the prior year.
  • Enterprise Value was -$170.9 million for Q1 2026 at Pliant Therapeutics, up from -$190.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$163.6 million in Q2 2022 and troughed at -$577.3 million in Q1 2023.
  • The 5-year median for Enterprise Value is -$355.7 million (2024), against an average of -$355.0 million.
  • Year-over-year, Enterprise Value crashed 239.35% in 2023 and then soared 46.32% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$331.2 million in 2022, then tumbled by 49.23% to -$494.2 million in 2023, then increased by 28.03% to -$355.7 million in 2024, then soared by 46.32% to -$190.9 million in 2025, then grew by 10.5% to -$170.9 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Enterprise Value are -$170.9 million (Q1 2026), -$190.9 million (Q4 2025), and -$241.8 million (Q3 2025).